RESUMEN
Infections in burn patients are usually caused by multidrug-resistant micro-organisms. Tigecycline, a derivative of glycylcyclines, is an effective antibiotic against the resistant strains. The aim of this study is to determine the in vitro activity of tigecycline against the multidrug-resistant bacteria isolated from burn patients. Fourty-seven bacteria isolated from 118 patients hospitalized in the burn unit during 2003-2006 were included in the study. Gram-negative bacteria that were resistant to at least six broad-spectrum antibiotics, methicillin-resistant staphylococci and ampicillin-resistant enterococci were studied. Minimal inhibitory concentration values of tigecycline against these bacteria were tested by E-test strips. Susceptibility breakpoints were determined according to the previous studies; Asunto(s)
Antibacterianos/farmacología
, Quemaduras/microbiología
, Farmacorresistencia Bacteriana Múltiple
, Bacterias Gramnegativas/efectos de los fármacos
, Minociclina/análogos & derivados
, Acinetobacter/efectos de los fármacos
, Técnicas Bacteriológicas
, Quemaduras/tratamiento farmacológico
, Enterococcus/efectos de los fármacos
, Bacterias Gramnegativas/aislamiento & purificación
, Humanos
, Resistencia a la Meticilina/efectos de los fármacos
, Pruebas de Sensibilidad Microbiana
, Minociclina/farmacología
, Staphylococcus aureus/efectos de los fármacos
, Tigeciclina